ATLC Stock Analysis: Atlanticus Holdings | NASDAQ
Credit Services | NASDAQ, USA | Market Cap: 1.457m USD | 12M Return: 72.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.5M
EPS Trend: 91.5%
Qual. Beats: 1
Rev. Trend: 92.7%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Atlanticus Holdings Corporation (NASDAQ: ATLC) is a U.S.-based financial technology company that provides credit products and related services to lenders, operating through two main segments: Credit as a Service (CaaS) and Auto Finance. The CaaS segment issues private label credit cards focused on healthcare (under the Curae brand) as well as consumer electronics, furniture, elective medical procedures, and home improvement (under the Fortiva brand and partners brands), along with general-purpose credit cards marketed under the Aspire, Imagine, Mercury, and Fortiva names. These products are originated through bank partnerships and distributed via retail and healthcare point-of-sale locations, direct mail, digital marketing, and third-party partnerships. The CaaS segment also provides loan servicing-including risk management and customer service outsourcing-and conducts product testing and investments.
The Auto Finance segment purchases and services loans secured by automobiles sourced from a pre-qualified network of independent automotive dealers and finance companies operating in the buy-here, pay-here used car market, and additionally provides floor plan financing and installment lending products. Atlanticus falls within the GICS Consumer Finance sub-industry, a sector that typically serves near-prime and subprime borrowers through specialized credit offerings, and the company has been operating since its 1996 founding, with its headquarters in Atlanta, Georgia.
- Net interest margin compresses on rising funding costs for card portfolios
- Credit loss provisions increase as subprime delinquencies trend higher
- CaaS segment receivables expand with new healthcare and retail partner additions
| Net Income: 134.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.77 > 1.0 |
| NWC/Revenue: 29.41% < 20% (prev 55.01%; Δ -25.60% < -1%) |
| CFO/TA 0.11 > 3% & CFO 792.7m > Net Income 134.9m |
| Net Debt (5.57b) to EBITDA (312.3m): 17.85 < 3 |
| Current Ratio: 1.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.2m) vs 12m ago 1.31% < -2% |
| Gross Margin: 75.06% > 18% (prev 61.77%; Δ 13.28% > 0.5%) |
| Asset Turnover: 23.27% > 50% (prev 14.96%; Δ 8.31% > 0%) |
| Interest Coverage Ratio: 0.80 > 6 (EBIT TTM 300.5m / Interest Expense TTM 377.1m) |
| A: 0.05 (Total Current Assets 804.1m - Total Current Liabilities 436.7m) / Total Assets 7.47b |
| B: 0.07 (Retained Earnings 548.3m / Total Assets 7.47b) |
| C: 0.06 (EBIT TTM 300.5m / Avg Total Assets 5.37b) |
| D: 0.10 (Book Value of Equity 688.4m / Total Liabilities 6.78b) |
| Altman-Z'' = 1.04 = BB |
As of July 10, 2026, the stock is trading at USD 98.24 with a total of 195,236 shares traded. Over the past week, the price has changed by -5.31%, over one month by +10.66%, over three months by +55.15% and over the past year by +72.41%.
Current recommended Stop Loss: 89.30 (which is 9.1% or 1.4 ATR below the current price).
Atlanticus Holdings has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ATLC.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 118.8 | 20.9% |
P/E Trailing = 11.4762
P/E Forward = 6.8074
P/S = 2.3174
P/B = 1.7943
Revenue TTM = 1.25b USD
EBIT TTM = 300.5m USD
EBITDA TTM = 312.3m USD
Long Term Debt = 6.33b USD (from longTermDebt, last quarter)
Short Term Debt = 78.4m USD (from shortTermDebt, last quarter)
Debt = 6.38b USD (from shortLongTermDebtTotal, last quarter) + Leases 24.5m
Net Debt = 5.57b USD (calculated: Debt 6.38b - CCE 804.1m)
Enterprise Value = 7.03b USD (1.46b + Debt 6.38b - CCE 804.1m)
Interest Coverage Ratio = 0.80 (Ebit TTM 300.5m / Interest Expense TTM 377.1m)
EV/FCF = 47.59x (Enterprise Value 7.03b / FCF TTM 147.8m)
FCF Yield = 2.10% (FCF TTM 147.8m / Enterprise Value 7.03b)
FCF Margin = 11.83% (FCF TTM 147.8m / Revenue TTM 1.25b)
Net Margin = 10.79% (Net Income TTM 134.9m / Revenue TTM 1.25b)
Gross Margin = 75.06% ((Revenue TTM 1.25b - Cost of Revenue TTM 311.6m) / Revenue TTM)
Gross Margin QoQ = 92.34% (prev 48.55%)
Tobins Q-Ratio = 0.94 (Enterprise Value 7.03b / Total Assets 7.47b)
Interest Expense / Debt = 5.91% (Interest Expense 377.1m / Debt 6.38b)
Taxrate = 24.55% (43.6m / 177.7m)
NOPAT = 226.7m (EBIT 300.5m * (1 - 24.55%))
Current Ratio = 1.16 (Total Current Assets 804.1m / Total Current Liabilities 695.0m)
Debt / Equity = 9.27 (Debt 6.38b / totalStockholderEquity, last quarter 688.4m)
Debt / EBITDA = 17.85 (Net Debt 5.57b / EBITDA 312.3m)
Debt / FCF = 37.73 (Net Debt 5.57b / FCF TTM 147.8m)
Total Stockholder Equity = 622.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.51% (Net Income 134.9m / Total Assets 7.47b)
RoE = 21.67% (Net Income TTM 134.9m / Total Stockholder Equity 622.5m)
RoCE = 4.32% (EBIT 300.5m / Capital Employed (Equity 622.5m + L.T.Debt 6.33b))
RoIC = 3.06% (NOPAT 226.7m / Invested Capital 7.40b)
WACC = 5.65% (E(1.46b)/V(7.84b) * Re(10.88%) + D(6.38b)/V(7.84b) * Rd(5.91%) * (1-Tc(0.25)))
Discount Rate = 10.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.68 | Cagr: 1.15%
[DCF] Terminal Value 77.97% ; FCFF base≈137.8m ; Y1≈157.9m ; Y5≈232.4m
[DCF] Fair Price = N/A (negative equity: EV 3.50b - Net Debt 5.57b = -2.08b; debt exceeds intrinsic value)
EPS Correlation: 91.46 | EPS CAGR: 20.31% | SUE: 3.01 | # QB: 1
Revenue Correlation: 92.70 | Revenue CAGR: 51.02% | SUE: -0.19 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.49 | Chg30d=+0.00% | Revisions=+57% | Analysts=4
EPS next Quarter (2026-09-30): EPS=2.71 | Chg30d=+0.00% | Revisions=-29% | Analysts=4
EPS current Year (2026-12-31): EPS=9.63 | Chg30d=+0.00% | Revisions=+57% | GrowthEPS=+61.6% | GrowthRev=+51.2%
EPS next Year (2027-12-31): EPS=13.34 | Chg30d=+0.00% | Revisions=+29% | GrowthEPS=+38.5% | GrowthRev=+13.2%
[Analyst] Revisions Ratio: +42% (up=12, down=4)